Title: AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
Associated condition: NASH
Status: Currently enrolling
Brief summary: This is a double-blind placebo controlled randomized 2-part Phase 3 study in subjects with nonalcoholic steatohepatitis (NASH) and Stage 2 or 3 liver fibrosis. Subjects will receive 150 mg cenicriviroc QD or matching placebo.
Primary objectives: To confirm the efficacy and safety of cenicriviroc (CVC) compared to placebo for the treatment of Stage 2 or 3 liver fibrosis in adult subjects with NASH.
Estimated length of study: Time to accrue a pre-specified number of adjudicated events, End of Study, with an estimate that the study to be fully completed in 5 years.
Time to accrue a pre-specified number of adjudicated events, End of Study, estimated to be 5 years.
For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.
